A ruling in a patent law case regarding an anti-cholesterol drug set the stage for a sharp run-up in the shares of Thousand Oaks biotech giant Amgen. Amgen had filed its patent infringement lawsuit against Sanofi and Regeneron in the U.S. District Court of Delaware in October 2014. The suit sought to block the development…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
